4 results match your criteria: "Neuro-Uro-Andrology R. Poincare Academic Hospital[Affiliation]"
Nocturia and obstructive sleep apnea in spinal cord injured patients - a cohort study.
World J Urol
September 2024
GHU Paris Saclay, Neuro-Uro-Andrology R. Poincare Academic Hospital, AP-HP, Hôpital Raymond Poincaré, Garches, France.
Purpose: To describe the prevalence of nocturia and obstructive sleep apnea (OSA) in a cohort of spinal cord injury (SCI) patients and to describe their association. Additionally, to assess clinical and urodynamic data explaining nocturia and to evaluate the effect of OSA management with continuous positive airway pressure (CPAP).
Method: Retrospective analysis of data from patients with SCI followed in a tertiary care rehabilitation center with a specialized sleep and neuro-urology units.
Acute Intravesical Capsaicin for the Study of TRPV1 in the Lower Urinary Tract: Clinical Relevance and Potential for Innovation.
Med Sci (Basel)
September 2022
Faculty of Medicine, U1179 Inserm/Versailles Saint Quentin University, Paris Saclay, 78180 Montigny-le-Bretonneux, France.
Article Synopsis
- Capsaicin, a compound found in chili peppers, interacts with sensory nerves through vanilloid receptors, particularly TRPV1, which is important for understanding lower urinary tract conditions in both rodents and humans.
- The study reviews the use of acute intravesical capsaicin instillation (AICI) in animal models to simulate disorders like overactive bladder (OAB) and neurogenic detrusor overactivity (NDO), highlighting the role of capsaicin-sensitive C-fibers in these conditions.
- The AICI model shows promise for developing new treatments targeting these C-fiber afferents and providing insights into related bladder disorders, suggesting a focus on TRPV1 channel blockade as a potential therapeutic approach.
Long Term Effectiveness and Safety of Intracavernosal Botulinum Toxin A as an Add-on Therapy to Phosphosdiesterase Type 5 Inhibitors or Prostaglandin E1 Injections for Erectile Dysfunction.
J Sex Med
January 2022
Neuro-Uro-Andrology R.Poincare academic hospital, Garches, France; Faculty of Medicine, U1179 Inserm / Versailles Saint Quentin University, Montigny le Bretonneux, Paris Saclay, France.
Background: Some evidence suggests that intracavernosal botulinum toxin A (BTX-A IC) injections administered in addition to phosphodiesterase type 5 inhibitors (PDE5-Is) or prostaglandin E1 intracavernosal injections (PGE1 ICI) could effectively treat erectile dysfunction (ED) in non-responders, or insufficient responders to these pharmacologic treatments.
Aim: To determine the long-term effectiveness and safety of combined treatment involving a single injection of BTX-A IC as an add on therapy to PDE5-Is or PGE1-ICI for the treatment of ED of different etiologies.
Methods: A retrospective, uncontrolled, single center study was conducted.
Safety and Efficacy of Intracavernosal Injections of AbobotulinumtoxinA (Dysport) as Add on Therapy to Phosphosdiesterase Type 5 Inhibitors or Prostaglandin E1 for Erectile Dysfunction-Case Studies.
Toxins (Basel)
May 2019
Neuro-Uro-Andrology R.Poincare academic hospital, AP-HP, 104 bvd R. Poincare, 92380 Garches, France.
Erectile dysfunction (ED) is a highly prevalent condition with a variety of possible risk factors and/or etiologies. Despite significant advances regarding ED pharmacological management, there are still insufficient responders to existing pharmacological treatments e.g.
View Article and Find Full Text PDF